Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.15
+0.10 (1.24%)
Jan 21, 2025, 4:00 PM EST - Market closed
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 21.2, with a low estimate of 17 and a high estimate of 25. The average target predicts an increase of 160.12% from the current stock price of 8.15.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 20, 2024.
Analyst Ratings
The average analyst rating for ZVRA stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +145.40% | Nov 20, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $25 → $23 | Strong Buy | Maintains | $25 → $23 | +182.21% | Nov 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 11, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +145.40% | Sep 30, 2024 |
Financial Forecast
Revenue This Year
20.72M
from 27.46M
Decreased by -24.57%
Revenue Next Year
100.39M
from 20.72M
Increased by 384.62%
EPS This Year
-2.03
from -1.30
EPS Next Year
-0.36
from -2.03
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 24.7M | 179.0M | 222.6M | |||
| Avg | 20.7M | 100.4M | 174.6M | |||
| Low | 17.2M | 58.5M | 145.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -9.9% | 764.3% | 121.7% | |||
| Avg | -24.6% | 384.6% | 74.0% | |||
| Low | -37.2% | 182.4% | 44.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.02 | 0.89 | 1.42 | |||
| Avg | -2.03 | -0.36 | 0.72 | |||
| Low | -2.10 | -1.31 | 0.25 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.